New evidence suggests that obesity doesn’t just affect the body — it may also accelerate the brain’s decline in Alzheimer’s disease. But here’s where things get even more compelling: the changes can now be traced through blood tests, long before major symptoms appear.
A groundbreaking long-term study has found that people living with obesity experience Alzheimer’s-related changes in the brain much faster than those with a healthy weight. Over a five-year observation period involving 407 participants from the Alzheimer’s Disease Neuroimaging Initiative, researchers tracked blood-based biomarkers and discovered that Alzheimer’s markers like pTau217, neurofilament light chain (NfL), and amyloid proteins increased 29% to 95% faster in individuals with obesity. PET scans also showed a 3.7% quicker buildup of amyloid plaques, and blood tests revealed a 24% quicker rise in NfL, signaling heightened nerve-cell degeneration.
According to senior author Dr. Cyrus Raji of Washington University’s Mallinckrodt Institute of Radiology, “This is the first time we’ve been able to document the connection between obesity and Alzheimer’s disease progression using blood biomarker testing.” The findings were presented at the Radiological Society of North America’s (RSNA) annual meeting in Chicago.
The researchers measured key Alzheimer’s biomarkers — pTau217, NfL, and GFAP — using six standardized commercial assays, in combination with amyloid PET imaging. This approach allowed them to analyze how obesity shaped the progression of disease indicators over time. Crucially, the longitudinal format revealed patterns that single, one-time measurements might have missed.
At first glance, higher body mass index (BMI) seemed linked to lower biomarker levels and less amyloid in the brain — a somewhat counterintuitive finding. But as lead author Dr. Soheil Mohammadi explained, “Those early differences likely result from dilution due to greater blood volume in obese individuals. When you rely only on baseline data, you might wrongly assume obesity lowers Alzheimer’s risk. It’s only through tracking these patients over time that the faster disease progression becomes clear.”
Across five years, participants with obesity showed steeper increases in blood biomarkers — in some cases, nearly doubling the rates of change compared with participants at a normal weight. These patterns aligned with increased amyloid accumulation seen on brain imaging, highlighting obesity as a critical, modifiable risk factor for dementia.
Interestingly, the study uncovered subtle differences between what blood tests and PET imaging reveal. “What surprised me most,” Dr. Raji noted, “is that blood biomarkers appear even more sensitive than PET scans in detecting the impact of obesity on Alzheimer’s progression.” This finding could reshape how clinicians monitor at-risk patients in the future.
Dr. Mohammadi pointed out that these insights underscore the role of lifestyle and weight management in preventing or delaying cognitive decline. Referring to the 2024 Lancet Commission report, he added, “Up to 45% of Alzheimer’s risk worldwide is linked to 14 modifiable factors. Tackling even one of them — such as obesity — could reduce overall disease rates or delay its onset.”
Looking ahead, both researchers envision a new era of personalized Alzheimer’s prevention. With advances in anti-obesity medications, scientists could soon study whether weight loss interventions can slow or even reverse Alzheimer’s-related biomarker changes. “It’s an incredibly exciting time,” said Dr. Raji. “We now have powerful drugs to manage obesity alongside precise blood and imaging tools to monitor brain health. This synergy could transform how we approach Alzheimer’s prevention and treatment.”
The study, presented by the Radiological Society of North America, marks a major step toward understanding how metabolic health influences cognitive decline. And it raises an important, and perhaps controversial, question: If obesity truly accelerates Alzheimer’s progression, should weight management become a standard part of dementia prevention strategies?
What do you think — should obesity treatments be prioritized as brain-protective therapies alongside traditional neurological care? Share your thoughts or argue your perspective in the comments below.
